Navigate Fool.com
Will MNTA beat
the market?
Community Rating: 4 Stars: Favorite

11.27 -0.22 (-1.91%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $11.56
Previous Close $11.49
Daily Range $11.01 - $11.66
52-Week Range $10.24 - $19.90
Market Cap $591.4M
P/E Ratio -5.39
Dividend (Yield) $0.00 (0.0%)
Volume 304,965
Average Daily Volume 1,169,698
Current FY EPS $0.29

How do you think MNTA
will perform against the market?

Top MNTA Bull/Bear Pitches


anchor68 (0)
Submitted September 16, 2011

One word says it all: Generics- People not only want Affordable medications, they Demand it!!!

0 Replies Reply Report this Post

zzlangerhans (< 20)
Submitted November 2, 2011

If you know anyone who claims to be an expert on biotech stocks, ask them if they know what's going to happen with Momenta Pharmaceuticals. If they start telling you what's going to happen, laugh and … More

1 Replies Reply Report this Post

News & Commentary Rss Feed

The Supreme Court Will Decide the Fate of a Blockbuster

Teva's day in court is coming.

Healthcare Stocks Continue Rebound; Momenta Pharma Advances After Supreme Court OKs Generic MS Drug

Healthcare Stocks Continue Rebound; Momenta Pharma Advances After Supreme Court OKs Generic MS Drug Sales

Sector Update: Healthcare

3 Horrendous Health-Care Stocks This Week

Find out which health-care stocks ended up as the past week's worst losers.

Why MannKind, Momenta Pharmaceuticals, and Idera Pharmaceuticals Tumbled Today

Janet Yellen's comments sent stocks higher, but these three companies missed out. Find out why these stocks fell sharply today.

Legal Woes Piling Up for Teva Pharmaceutical Industries Ltd

Lately Teva's been having legal trouble, from Supreme Court silence, to the loss of a patent dispute with Mylan.

Teva’s Latest Victory in Effort to Protect Key Patents

Supreme Court Ignores Teva Pharmaceuticals Ltd's Pleas for Help

Teva faces patent expiration on its $4 billion-a-year Copaxone in May.

Teva: Attempting to Dodge Wrenches

The threat to $4 billion in sales for Teva's (TEVA) blockbuster Copaxone has the company making moves to protect its MS market share.

9 Top Stocks to Buy in 2014

We asked nine of our top analysts for their favorite stock ideas for the year ahead. Here are the nine companies they selected.

See More MNTA News...





Momenta Pharmaceuticals (MNTA) Description

A biotechnology company specializing in the detailed structural analysis of complex mixture drugs of the development of generic or biosimilar versions of complex drug products as well as to the discovery and development of novel drugs. Website: http://www.momentapharma.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks